Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2023 20:47 ET | Source: Mesoblast Limited

Mesoblast Completes Private Placement

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a...
March 21, 2023 21:20 ET | Source: Mesoblast Limited

FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing

Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved,...
March 07, 2023 19:03 ET | Source: Mesoblast Limited

FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United...
February 27, 2023 17:13 ET | Source: Mesoblast Limited

Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022

NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
February 27, 2023 16:49 ET | Source: Mesoblast Limited

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the...
February 26, 2023 19:38 ET | Source: Mesoblast Limited

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
February 16, 2023 18:16 ET | Source: Mesoblast Limited

Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on...
February 08, 2023 18:09 ET | Source: Mesoblast Limited

FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States...
January 31, 2023 18:30 ET | Source: Mesoblast Limited

Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with...
January 31, 2023 04:40 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...